October 2, 2012 — AstraZeneca has announced the results from a sub-analysis of PLATO that evaluated the effects of age on clinical outcomes in patients with acute coronary syndrome (ACS). Results of the analysis suggest the overall findings from the PLATO study of a greater reduction in thrombotic cardiovascular (CV) events with Brilinta (ticagrelor) tablets plus aspirin compared to clopidogrel plus aspirin were consistent regardless of age.
